NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced the results of operations for the third quarter and nine months ended September 30, 2007. The Company recognized revenues from grants and contracts of $1.6 million for the quarter ended September 30, 2007, as compared to $2 million for the same quarter of the prior year. Operating loss for the quarter was $1.6 million as compared to approximately $1 million for the comparable quarter of the previous year. The recognition of a non-cash charge of $1 million reflecting a decline of the fair market value of certain rights and warrants to purchase common shares of the Company resulted in loss per share, on a diluted basis, of ($0.07) as compared to a loss of ($0.02) for the same period last year.
